-
Product Insights
NewCharcot-Marie-Tooth Disease Type I – Drugs In Development, 2024
Empower your strategies with our Charcot-Marie-Tooth Disease Type I – Drugs In Development, 2024 report and make more profitable business decisions. Charcot-Marie-Tooth disease, a group of hereditary sensory and motor neuropathies affecting peripheral nerves, leads to progressive damage connecting the brain and spinal cord to muscles and sensory cells. Manifesting in adolescence or adulthood, it causes sensation alteration, muscle wasting, and varying physical disabilities. Initial symptoms involve muscle atrophy in the feet, often accompanied by foot abnormalities, and difficulties in flexing...
-
Product Insights
NewCharcot-Marie-Tooth Disease – Drugs In Development, 2024
Empower your strategies with our Charcot-Marie-Tooth Disease – Drugs In Development, 2024 report and make more profitable business decisions. Charcot-Marie-Tooth disease (CMT) is a term for a group of inherited genetic disorders that affect the peripheral nerves, which connect the brain and spinal cord to the muscles and sensory organs. CMT causes progressive weakness, muscle wasting, and loss of sensation in the feet, legs, hands, and arms. It can also cause foot deformities such as high arches or flat feet. CMT...
-
Product Insights
NewCharcot-Marie-Tooth Disease Type I A – Drugs In Development, 2024
Empower your strategies with our Charcot-Marie-Tooth Disease Type I A – Drugs In Development, 2024 report and make more profitable business decisions. Charcot–Marie–Tooth disease type 1A (CMT1A), the most frequent form of CMT, is caused by a 1.5 Mb duplication on the short arm of chromosome 17. CMT1 is characterized by muscle weakness and atrophy, which can lead to repeated ankle sprains, and changes in sensation (paresthesia), which can cause clumsiness. Symptoms of this form of CMT usually start in childhood...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (acamprosate calcium + baclofen)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (acamprosate calcium + baclofen) Drug Details A fixed dose combination of acamprosate and baclofen...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (baclofen + naltrexone hydrochloride + sorbitol)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (baclofen + naltrexone hydrochloride + sorbitol) Drug Details PXT-3003 is under development for the...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...